| Literature DB >> 25937947 |
Saumya K Patel1, Linz-Buoy George2, Sivakumar Prasanth Kumar3, Hyacinth N Highland2, Yogesh T Jasrai3, Himanshu A Pandya3, Ketaki R Desai2.
Abstract
The emergence of drug resistance in Plasmodium falciparum tremendously affected the chemotherapy worldwide while the intense distribution of chloroquine-resistant strains in most of the endemic areas added more complications in the treatment of malaria. The situation has even worsened by the lack of molecular mechanism to understand the resistance conferred by Plasmodia species. Recent studies have suggested the association of antimalarial resistance with P. falciparum multidrug resistance protein 1 (PfMDR1), an ATP-binding cassette (ABC) transporter and a homologue of human P-glycoprotein 1 (P-gp1). The present study deals about the development of PfMDR1 computational model and the model of substrate transport across PfMDR1 with insights derived from conformations relative to inward- and outward-facing topologies that switch on/off the transportation system. Comparison of ATP docked positions and its structural motif binding properties were found to be similar among other ATPases, and thereby contributes to NBD domains dimerization, a unique structural agreement noticed in Mus musculus Pgp and Escherichia coli MDR transporter homolog (MsbA). The interaction of leading antimalarials and phytochemicals within the active pocket of both wild-type and mutant-type PfMDR1 demonstrated the mode of binding and provided insights of less binding affinity thereby contributing to parasite's resistance mechanism.Entities:
Year: 2013 PMID: 25937947 PMCID: PMC4393060 DOI: 10.1155/2013/437168
Source DB: PubMed Journal: ISRN Bioinform ISSN: 2090-7338
Figure 13D model of developed PfMDR1.
Figure 2Ramachandran map and quality index of template M. musculus P-gp1 (a) and modeled PfMDR1 (b).
Figure 3Structural superposition of M. Musculus P-gp and PfMDR1 model.
Figure 4WHISCY predictions at the NBD dimer site of PfMDR1.
List of amino acids predicted to be localized at the NBDs interface site.
| Domainsa | Amino acids interacting at the NBDs dimer siteb,c |
|---|---|
| NBD I | 388: Asp (0.70), 389: Thr (1.27), 390: Arg (0.94), 391: Lys (1.01), 392: Asp (0.69), 414: Glu (1.39), 415: Ser (1.28), 429: Leu (1.18), 462: Gln (0.73), 463: Asp (1.03), 465: Leu (1.08), 467: Phe (1.10), 468: Ser (0.92), 469: Asn (0.26), 555: Leu (0.18), 558: Ser (0.45), 559: Asn (0.49), 561: Ser (0.33), 562: Lys (0.39), 563: Leu (0.89), 564: Ser (0.71), 565: Gly (0.41), 567: Gln (0.08), 588: Glu (0.43), 591: Ser (0.84), 592: Ser (1.49), 593: Leu (1.03), 594: Asp (1.67), 595: Asn (1.77), 596: Lys (1.16), 599: Tyr (0.73), 621: His (0.65), 624: Ser (0.33). |
|
| |
| NBD II | 1256: Gln (0.03), 1257: Glu (0.43), 1297: Leu (0.96), 1298: Pro (1.35), 1299: Asn (0.93), 1300: Lys (0.05), 1301: Tyr (0.11), 1302: Asp (0.20), 1303: Thr (0.47), 1304: Asn (0.05), 1306: Gly (0.83), 1307: Pro (0.80), 1310: Lys (0.57), 1311: Ser (0.72), 1312: Leu (0.87), 1313: Ser (0.84), 1316: Gln (1.33), 1317: Lys (0.42), 1319: Arg (0.97), 1337: Glu (0.26), 1340: Ser (0.64), 1341: Ser (0.32), 1342: Leu (0.12), 1343: Asp (1.23), 1344: Ser (0.16), 1346: Ser (0.27). |
aNBD: Nucleotide binding domain (I and II).
bNumber preceding the amino acids indicate sequence position.
cNumber within brackets indicate interfacial residue scores.
Figure 5Structural superposition of Eco-MsbA and PfMDR1 in their closed-apo forms (the NBD dimer sites of PfMDR1 are highlighted in red patches).
Figure 6ATP docked view of PfMDR1 NBD I and II.
Figure 7Structural view of SNP in wild-type (left) and mutant-type PfMDR1 (right).
Energetic details of ligand interaction with wild-type and mutant-type PfMDR1.
| Compounds | Type of straina | Amino acid interactionsb,c |
|---|---|---|
| Amodiaquine | wtPfMDR1 | H-bond: Tyr1046 |
| mtPfMDR1 | H-bond: Tyr1046 | |
|
| ||
| Artemisinin | wtPfMDR1 | H-bond: |
| mtPfMDR1 | H-bond: | |
|
| ||
| Calotropegenin | wtPfMDR1 | H-bond: Asn943(2), |
| mtPfMDR1 | H-bond: Asn943, | |
|
| ||
| Chloroquine | wtPfMDR1 | H-bond: None |
| mtPfMDR1 | H-bond: None | |
|
| ||
| Halofantrine | wtPfMDR1 | H-bond: |
| mtPfMDR1 | H-bond: | |
|
| ||
| Lumefantrine | wtPfMDR1 | H-bond: None |
| mtPfMDR1 | H-bond: None | |
|
| ||
| Mefloquine | wtPfMDR1 | H-bond: Gln1038, |
| mtPfMDR1 | H-bond: Gln1038 | |
|
| ||
| Vinblastine | wtPfMDR1 | H-bond: Gln1035(2) |
| mtPfMDR1 | H-bond: Gln1035(2) | |
|
| ||
| Vincristine | wtPfMDR1 | H-bond: None |
| mtPfMDR1 | H-bond: None | |
awtPfMDR1: wild-type PfMDR1.
amtPfMDR1: mutant-type PfMDR1.
bH-bond: Hydrogen bond.
bElec: Electrostatic interaction.
bvdW: van der Waals interaction.
cFunction residues are depicted in bold face.
cNumber within brackets indicate the number of H-bonds formed.
Figure 8Docked poses of (a-b) calotropegenin, (c-d) chloroquine, (e-f) vinblastine, and (g-h) vincristine in wtPfMDR1 and mtPfMDR1.